Dr. Logan Spector

And, you know, that's extremely concerning.

Before we get to the, you know, screening question, which is a great question, you know, we should definitely talk about why.

So I work with the International Agency for Research on Cancer.

It's called IARC.

It's in Lyon, France.

It's actually a branch of the WHO that's just concerned with tracking cancer around the world and also –

figuring out why people get cancer and then making recommendations to reduce cancer incidence, right?

And about 13 years ago, there was a guy in England who since was knighted for this, they realized that if you sequence a tumor, all right, like look at every DNA letter,

You can find and then you compare it to the normal tissue.

All right.

The normal DNA.

You can find what they called mutational signatures of of what might have that what that tumor might have gone through.

Right.

So it's it's not exactly a fingerprint of the cause, but it is a fingerprint of it's like journey, you know, like we all.

you know, we all have scars, whether they're physical or mental.

And, you know, so think of it as like a scar on the tumor's DNA.

And last year they published what they called a mutagraph study.

That was just looking at what the tumor looks like, but they collected them from, I think, a thousand colorectal cancers from different countries and at different ages.

And what they found was in the young onset colorectal cancer, there was a very high proportion, much higher than in the older cases, of a mutational signature of what's called colobactin toxin.

So we all have...